Effects of Behavior Modification Program for Delayed Nephropathy Progression in Diabetes Mellitus and Hypertension Patient with Chronic Kidney Disease Stage 1 to 3at DongKhwangSub-district, Mueang NakhonPhanom District, NakhonPhanom Province

Abstract

The quasi – experimental research (One group pretest – posttest design) aims to study effects of behavior modification program for delayed nephropathy progression in diabetes mellitus and hypertension patient with chronic kidney disease (CKD) stage 1 to 3 at Dong Khwang sub-district, MueangNakhonPhanom district, NakhonPhanom province. The samples were 50 chronic kidney disease stage 1 to 3 patients. The researcher selected the sample that passed the inclusion and exclusion criteria. Data distribution was performed by descriptive statistics were frequency, percentage, mean and inferential statistics Paired t-test was also utilized. The results showed that majority of the samples were female (37 people, 74percent) and 48 people hold primary education degree or higher (96 percent). Most of them married (32 people, 64percent) and 37 people got monthly income lower than 3,000 Baht (74 percent). More than haft of them agriculturist (34 people, 68 percent) and main of the participant were diabetes mellitus patients (35 people, 70 percent). The knowledge score about chronic kidney disease of patients before provides program were a low level at 36 percent but after provided program the participant has higher knowledge about chronic kidney disease score in significant level (p-value < 0.001). The patient’s self-care behavior score before provide program were poor level at 63 percent but after provided program the participant have patients self-care behavior score in good level at 92 percent; moreover after provided program the participants has higher patient’s self-care behavior score in significant level (p-value < 0.001) To encapsulate, before providing program the patients who got moderate decrease in Estimated Glomerular Filtration Rate (eGFR) (CKD stage 3) at 24 percent and kidney damage with a mild decrease in GFR (CKD stage 2) at 50 percent. After they received the program CKD patients stage 3 were decrease or stable at 12 percent and CKD patients stage 2 were increased at 60 percent. Patient’s eGFR after they received the program higher than baseline (p-value < 0.001).